The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The HPX domain contributes to the interaction of MT1-MMP with its substrates, such as CD44 and collagen.
“The HPX domain contributes to the interaction of MT1-MMP with its substrates, such as CD44 and collagen (54–57).”
From Identification of amino acid residues in the MT-loop of MT1-MMP critical for its ability to cleave low-density lipoprotein receptor (2022) · cites this paper as [57]
The section on PEX-domain motifs reports that a blade I mutant failed to coprecipitate with CD44, supporting a role for the domain in the MMP-14–CD44 interaction. The Discussion also describes CD44 cleavage by MMP-14. Our copy does not establish that the PEX domain contributes to interaction with collagen; searches for collagen binding and substrate interaction did not find such a passage. No page number was available in the indexed copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredThe HPX domain is required for MT1-MMP binding to CD44 and collagen.
“The HPX domain is required for MT1-MMP binding to CD44 and collagen.”
From Identification of amino acid residues in the MT-loop of MT1-MMP critical for its ability to cleave low-density lipoprotein receptor (2022) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Flagged first, then by citations
Research works printed but not linked: 52
- Roy, 2009, J. Clin. Oncol., 27, 5287, 10.1200/JCO.2009.23.5556 · DOI
- Lauer-Fields, 2009, J. Biol. Chem., 284, 24017, 10.1074/jbc.M109.016873 · DOI
- Poincloux, 2009, J. Cell Sci., 122, 3015, 10.1242/jcs.034561 · DOI
- Sabeh, 2009, J. Biol. Chem., 284, 23001, 10.1074/jbc.M109.002808 · DOI
- Itoh, 2006, J. Cell Physiol., 206, 1, 10.1002/jcp.20431 · DOI
- Stetler-Stevenson, 1993, Annu. Rev. Cell Biol., 9, 541, 10.1146/annurev.cb.09.110193.002545 · DOI
- Artym, 2006, Cancer Res., 66, 3034, 10.1158/0008-5472.CAN-05-2177 · DOI
- Mori, 2002, EMBO J., 21, 3949, 10.1093/emboj/cdf411 · DOI · Paper page
- Sato, 1994, Nature, 370, 61, 10.1038/370061a0 · DOI
- Lichte, 1996, FEBS Lett., 397, 277, 10.1016/S0014-5793(96)01206-9 · DOI
- Cha, 2002, J. Mol. Biol., 320, 1065, 10.1016/S0022-2836(02)00558-2 · DOI
- Tochowicz, 2011, J. Biol. Chem., 286, 7587, 10.1074/jbc.M110.178434 · DOI
- Itoh, 2001, EMBO J., 20, 4782, 10.1093/emboj/20.17.4782 · DOI
- Cao, 2005, Thromb Haemost., 93, 770, 10.1160/TH04-08-0555 · DOI
- van de Vijver, 2002, N. Engl. J. Med., 347, 1999, 10.1056/NEJMoa021967 · DOI
- Wang, 2005, Lancet, 365, 671, 10.1016/S0140-6736(05)17947-1 · DOI
- Pawitan, 2005, Breast Cancer Res., 7, R953, 10.1186/bcr1325 · DOI
- Deryugina, 2008, Histochem. Cell Biol., 130, 1119, 10.1007/s00418-008-0536-2 · DOI
- Ribatti, 2006, Nat. Protoc., 1, 85, 10.1038/nprot.2006.13 · DOI
- Zucker, 2003, Curr. Top. Dev. Biol., 54, 1, 10.1016/S0070-2153(03)54004-2 · DOI
- Bode, 1999, Cell Mol. Life Sci., 55, 639, 10.1007/s000180050320 · DOI
- Pavlaki, 2002, J. Biol. Chem., 277, 2740, 10.1074/jbc.M108987200 · DOI
- Cao, 2004, J. Biol. Chem., 279, 14129, 10.1074/jbc.M312120200 · DOI
- Seiki, 2003, Cancer Metastasis Rev., 22, 129, 10.1023/A:1023087113214 · DOI
- Dufour, 2010, J. Biol. Chem., 285, 35944, 10.1074/jbc.M109.091769 · DOI
- Lehti, 2005, Genes Dev., 19, 979, 10.1101/gad.1294605 · DOI
- Khaldoyanidi, 2003, J. Biol. Chem., 278, 4127, 10.1074/jbc.M209590200 · DOI
- Price, 1996, Breast Cancer Res. Treat., 39, 93, 10.1007/BF01806081 · DOI
- Seraj, 2000, Cancer Res., 60, 2764
- Kirsch, 2004, Cancer Treat Res., 117, 285, 10.1007/978-1-4419-8871-3_17 · DOI
- Itoh, 2006, Mol. Biol. Cell, 17, 5390, 10.1091/mbc.e06-08-0740 · DOI
- Kajita, 2001, J. Cell Biol., 153, 893, 10.1083/jcb.153.5.893 · DOI
- Wang, 2004, J. Biol. Chem., 279, 51148, 10.1074/jbc.M409074200 · DOI
- Itoh, 2008, J. Biol. Chem., 283, 13053, 10.1074/jbc.M709327200 · DOI
- Li, 2008, Mol. Biol. Cell, 19, 3221, 10.1091/mbc.e08-01-0016 · DOI
- Sounni, 2010, Int. J. Cancer, 126, 1067, 10.1002/ijc.24690 · DOI
- Eisenach, 2010, J. Cell Sci., 123, 4182, 10.1242/jcs.062711 · DOI
- Cao, 2008, J. Biol. Chem., 283, 6232, 10.1074/jbc.M705759200 · DOI
- Remacle, 2005, J. Cell Sci., 118, 4975, 10.1242/jcs.02610 · DOI
- Okamoto, 1999, Oncogene, 18, 1435, 10.1038/sj.onc.1202447 · DOI
- Marrero-Diaz, 2009, Cell Motil. Cytoskeleton, 66, 48, 10.1002/cm.20325 · DOI
- Suenaga, 2005, Oncogene, 24, 859, 10.1038/sj.onc.1208258 · DOI
- Anderegg, 2009, J. Invest. Dermatol., 129, 1471, 10.1038/jid.2008.323 · DOI
- Verma, 2007, Bioorg. Med. Chem., 15, 2223, 10.1016/j.bmc.2007.01.011 · DOI
- Devy, 2009, Cancer Res., 69, 1517, 10.1158/0008-5472.CAN-08-3255 · DOI
- Gálvez, 2001, J. Biol. Chem., 276, 37491, 10.1074/jbc.M104094200 · DOI
- Sounni, 2002, FASEB J., 16, 555, 10.1096/fj.01-0790com · DOI
- D'Alessio, 2008, J. Biol. Chem., 283, 87, 10.1074/jbc.M705492200 · DOI
- Rozanov, 2004, Exp. Cell Res., 293, 81, 10.1016/j.yexcr.2003.10.006 · DOI · Paper page
- Magenta, 2008, BMC Cancer, 8, 47, 10.1186/1471-2407-8-47 · DOI
- Giubellino, 2007, Cancer Res., 67, 6012, 10.1158/0008-5472.CAN-07-0022 · DOI
- Dufour, 2008, J. Cell Physiol., 217, 643, 10.1002/jcp.21535 · DOI
Cited by
Sorted by citations
Barriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer
Li, W., Ng, J. M.-K., Wong, C. C., Ng, E. K. W., & Yu, J. (2018) · Oncogene · doi:10.1038/s41388-018-0341-x · Cited by 87
CTR1 Silencing Inhibits Angiogenesis by Limiting Copper Entry into Endothelial Cells
Narayanan, G., R., B. S., Vuyyuru, H., Muthuvel, B., & Konerirajapuram Natrajan, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071982 · Cited by 83
Wang, M., Alabi, A., Gu, H.-M., Gill, G., Zhang, Z., Jarad, S., Xia, X.-D., Shen, Y., Wang, G.-Q., & Zhang, D.-W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.917238 · Cited by 13
Metadata
- Authors
- Zarrabi, K., Dufour, A., Li, J., Kuscu, C., Pulkoski-Gross, A., Zhi, J., Hu, Y., Sampson, N. S., Zucker, S., & Cao, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 286
- Issue
- 38
- Pages
- 33167-33177
- ISSN
- 0021-9258
- Cited by
- 188
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
